FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.